6.89K
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer.

Similar securities

Based on sector and market capitalization

Report issue